Home | All trials

[RDF data]
Trial NCT00000218

Resource URI: http://static.linkedct.org/resource/trials/NCT00000218
PropertyValue
linkedct:brief_title Pharmacotherapy and Intensive Treatment - 2
linkedct:collaborator_agency <http://static.linkedct.org/resource/collabagency/2124>
linkedct:condition <http://static.linkedct.org/resource/condition/12664>
linkedct:condition <http://static.linkedct.org/resource/condition/2992>
linkedct:criteria Please contact site for information.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Female
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 60 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:end_date June 2005
linkedct:enrollment 353 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000218
rdfs:label Trial NCT00000218
linkedct:lastchanged_date March 23, 2009
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/195349>
linkedct:nct_id NCT00000218
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Pharmacotherapy and Intensive Treatment
linkedct:org_study_id NIDA-06954-2
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/61447>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000218>
linkedct:phase Phase 4
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/20379>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/6422>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/6437>
linkedct:secondary_id R18-06954-2
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:study_design Treatment
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.
rdf:type linkedct:trials
linkedct:verification_date March 2009